Evidence map›Paper›PMID 41940034›Full record

ArticleNon-coding RNA research2026

CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma.

Zhengwei Yu, Xinyue Wang, Yiqian Zheng, Yifan He, Jiayu Lin, Yue Xiao, Bin Mo, Haoyu Xie, Sitong Hang, Xia Gao and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Non-coding RNA research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Zhengwei YuDepartment of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Xinyue WangResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, China.
Yiqian ZhengDepartment of Pathology, Taizhou People's Hospital Affiliated to Nanjing Medical University, Taizhou, 225300, Jiangsu Province, China.
Yifan HeDepartment of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Jiayu LinDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yue XiaoDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Bin MoDepartment of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Haoyu XieDepartment of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Sitong HangDepartment of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Xia GaoDepartment of Pulmonary and Critical Care Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Pei XuDepartment of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Yihao LiuDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Haibo XiaoDepartment of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) progression is strongly shaped by tumor-associated macrophages (TAMs), yet the post-transcriptional mechanisms that sustain matrix-remodeling TAM states remain incompletely understood. Here, circRNA profiling of LUAD TAMs versus normal tissue-resident macrophages identified circSMAD4 (hsa_circ_0047713) as a consistently TAM-enriched circRNA associated with advanced clinicopathological features and unfavorable survival. circSMAD4 exhibited canonical circular properties, including a validated back-splice junction, RNase R resistance, and enhanced transcript stability. Functionally, circSMAD4 knockdown in human and murine macrophages attenuated tumor education, shifted macrophages away from an M2-like phenotype, and weakened their ability to promote LUAD-cell proliferation, invasion, and EMT-like changes in co-culture. In syngeneic orthotopic lung and experimental metastasis models, circSMAD4-depleted macrophages restrained tumor growth and reduced metastatic burden. Mechanistically, cytoplasmic circSMAD4 acted as a ceRNA to sequester miR-562 and relieve repression of COL4A1. In parallel, circSMAD4 formed a specific ribonucleoprotein complex with the m6A reader IGF2BP2, facilitating IGF2BP2 association with COL4A1, ACTA2, and SPI1 transcripts and enhancing their m6A-dependent stability. Together, these dual branches converge on a matrix-remodeling output, positioning circSMAD4 as a post-transcriptional hub that reinforces protumor TAM programs in LUAD and a potential target for microenvironment-directed therapy.

Indexed as

circSMAD4IGF2BP2Lung adenocarcinomam6AMatrix-remodeling TAMs

Identifiers

PMID41940034
PMCPMC13050104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.